Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

Hyderabad:  Aurobindo Pharma Ltd wholly owned step-down subsidiary CuraTeQ Biologics has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, its pegylated filgrastim biosimilar…

Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

Aurobindo Pharma shares jumped 5 per cent on Friday, April 11, 2025, logging an intraday high at ₹1,110 per share on BSE. The stock rallied after the company’s subsidiary, CuraTeQ…

Aurobindo Pharma arm gets European Commission authorization to market Dyrupeg in EU

Telangana:  Aurobindo Pharma has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for Dyrupeg, a pegylated filgrastim biosimilar, to CuraTeQ Biologics s.r.o., a…

Aurobindo Pharma shares jump 2% after UK arm secures regulatory approval for cancer drug

Aurobindo Pharma shares jumped 2% to an intraday high of Rs 1,265 on the BSE after its wholly owned step-down subsidiary CuraTeQ Biologics received approval from the UK‘s Medicines and Healthcare products Regulatory Agency…